SCHOTT Pharma has announced an investment of €100m ($114m) to expand its manufacturing capacity for sterile RTU cartridges.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.